Today's biotech news, and what it means for each Thesis.

Akebia: VOICE primary endpoint met for Vafseo; secondary hemoglobin and ESA rescue data

Akebia Therapeutics, Inc.

ArriVent: ARR-217 Phase 1 data at ESMO; advances to Phase 1b dose optimization

ArriVent BioPharma, Inc.

Climb Bio: PrisMN 200 mg Week 12 immunologic activity; MCD single-patient case study

Climb Bio Inc

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals, Inc.

Iovance: ESMO pilot data in sarcoma; SARATOGA trial enrolling at U.S. centers

Iovance Biotherapeutics, Inc.

Nuvectis: NXP200 ESMO glioma data; China Breakthrough designation; Haisco rights deal; IND on track

Nuvectis Pharma, Inc.

Summit: HARMONi-GI1 meets OS and PFS endpoints; ECOG-ACRIN EA2251 collaboration

Summit Therapeutics Inc.

ORIC: enozertinib ESMO data; FDA End-of-Phase 1 completed; Redwood-1 Phase 3 planned; rinzimetostat preclinical

ORIC Pharmaceuticals, Inc.

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Ardelyx, Inc.

Ionis: sefaxersen meets Phase 3 proteinuria endpoint; Roche to share data with regulators

Ionis Pharmaceuticals, Inc.

Acumen: going concern doubt; ALTITUDE-AD results due November 2026; EBD option exercised

Acumen Pharmaceuticals, Inc.

Phase 3 design agreed and sites active around year-end

Perspective Therapeutics, Inc.

Challenged→BrokenBolt: Prana merger completed; $120M private placement; PRA-216 Phase 2 studies initiated

Bolt Biotherapeutics, Inc.

IDEAYA: IDE849 ESMO update; Phase 3 trials targeted after FDA meetings; dose selection underway

IDEAYA Biosciences, Inc.

Up to $50M common stock purchase agreement with Roth Principal Investments

Traws Pharma, Inc.

Intact→ChallengedArbutus: FDA lifts clinical hold on AB-101; Phase 1a/1b safety and exploratory data

Arbutus Biopharma Corporation

Fractyl: Rejuva discontinued; 45% workforce cut; REMAIN-1 six-month readout met endpoint; Caplan retiring

Fractyl Health, Inc.

Forbearance period extended to November 1, 2026

Karyopharm Therapeutics Inc.

Lucid: EsoGuard Medicare payments begin; $15.0M Series C placement; noteholders address default concern

Lucid Diagnostics Inc.

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics, Inc.